国际医学(000516) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,185,795,210.25, representing a 4.58% increase year-over-year[3] - The net profit attributable to shareholders was -¥38,503,140.17, a significant decrease of 60,252.12% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥80,627,749.25, an increase of 14.85% year-over-year[3] - Total operating revenue for Q3 2024 reached ¥3,606,256,924.42, an increase of 7.85% compared to ¥3,343,661,725.08 in Q3 2023[13] - The net loss for Q3 2024 was ¥294,272,771.90, compared to a net loss of ¥283,231,471.38 in Q3 2023, indicating a decline in profitability[14] - The company reported a basic and diluted earnings per share of -0.0954 for Q3 2024, compared to -0.0983 for the same period last year[14] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,554,066,876.37, down 6.78% from the end of the previous year[3] - The company's total assets decreased to ¥10,554,066,876.37 from ¥11,321,135,811.77, representing a decline of 6.77% year-over-year[12] - Total liabilities decreased to ¥7,075,540,848.59 from ¥7,505,045,119.83, a reduction of 5.73% compared to the previous year[12] - Shareholders' equity attributable to the parent company decreased to ¥3,652,616,319.10, a decline of 6.54% compared to the previous year[3] - The equity attributable to shareholders of the parent company was ¥3,652,616,319.10, while total equity amounted to ¥3,478,526,027.78[12] Cash Flow - Cash flow from operating activities for the year-to-date was ¥623,687,115.87, reflecting a decrease of 9.50% year-over-year[3] - The net cash flow from operating activities decreased to CNY 623,687,115.87 from CNY 689,153,979.24, reflecting a decline of 9.5%[15] - Cash inflow from operating activities for the current period was CNY 3,544,589,105.11, an increase of 8.3% compared to CNY 3,271,420,242.69 in the previous period[15] - The net cash flow from investing activities was negative at CNY -406,156,113.17, improving from CNY -616,922,958.32 in the previous period[15] - Cash inflow from financing activities totaled CNY 557,630,000.00, down from CNY 680,000,000.00, a decrease of 18.0%[16] - The net cash flow from financing activities was negative at CNY -734,010,695.10, worsening from CNY -469,134,181.46 in the previous period[16] Expenses - Total operating costs for Q3 2024 were ¥3,892,721,588.98, up from ¥3,731,857,156.74 in the same period last year, reflecting a year-over-year increase of 4.31%[13] - Research and development expenses decreased by 40.05% year-to-date compared to the same period last year[6] - Research and development expenses for Q3 2024 were ¥5,715,774.18, down from ¥9,533,885.43 in Q3 2023, showing a decrease of 40.5%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 107,360[7] - The company held 10,997,100 shares in its repurchase account, accounting for 0.49% of the total share capital[8] Current Assets - The total current assets decreased from CNY 1,912,895,613.76 to CNY 1,461,576,314.49, a decline of approximately 23.5%[10] - Cash and cash equivalents dropped significantly from CNY 943,962,638.82 to CNY 427,482,946.42, representing a decrease of about 54.7%[10] - Accounts receivable increased from CNY 661,684,668.02 to CNY 753,350,686.68, showing a growth of approximately 13.8%[10] - Inventory rose from CNY 78,336,971.70 to CNY 98,559,720.86, an increase of around 25.8%[10] - The total non-current assets decreased to ¥9,092,490,561.88 from ¥9,408,240,198.01, a decline of 3.35% year-over-year[12] Other Income and Expenses - The company reported a 429.52% increase in other income year-to-date, primarily due to debt restructuring gains[6] - The company reported a significant increase in prepaid expenses from CNY 6,869,617.24 to CNY 11,988,100.36, a rise of approximately 74.0%[10] Product Development and Strategy - The company did not disclose any new product developments or market expansion strategies during the conference call[9]